Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
December 08 2016 - 7:42AM
Business Wire
Speakers will share new data from Novocure’s
phase 2 pilot trials in pancreatic and ovarian cancers
Novocure (NASDAQ: NVCR) announced today the agenda for the
company’s research and development day for analysts and investors,
which will begin at 1 p.m. EST on Monday, Dec. 12, 2016, in New
York City.
The event will feature four speakers from Novocure and three
external medical experts who will provide analyses from completed
clinical trials, including the full, 695-patient trial cohort from
the EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma
(GBM), new data from the PANOVA phase 2 pilot trial in advanced
pancreatic cancer, new data from the INNOVATE phase 2 pilot trial
in recurrent ovarian cancer, and interim data from the STELLAR
phase 2 pilot trial in mesothelioma. Novocure also will provide an
update of recent preclinical findings related to Tumor Treating
Fields (TTFields) and a review of its ongoing clinical
pipeline.
Speakers include:
- William Doyle, Novocure’s
Executive Chairman
- Eilon Kirson, MD, PhD,
Novocure’s Chief Science Officer and Head of Research and
Development
- Uri Weinberg, MD, PhD,
Novocure’s Vice President of Research and Development
- Mike Ambrogi, Novocure’s Chief
Operating Officer
- Zvi Ram, MD, Director of
Neurosurgery at the Tel-Aviv Sourasky Medical Center in
Tel-Aviv
- Vinai Gondi, MD, Director of
Research at Northwestern Medicine Chicago Proton Center in
Chicago
- Daniel D. Von Hoff, MD, FACP,
Physician in Chief, Distinguished Professor Translational Research
Division at TGen (Translational Genomics Research Institute) in
Phoenix
Full agenda:
- 1 to 1:05 p.m.: Opening remarks, Mr.
Doyle
- 1:05 to 1:25 p.m.: Introduction to
TTFields and preclinical overview, Dr. Kirson
- 1:25 to 1:50 p.m.: TTFields and GBM,
and the full, 695-patient dataset from Novocure’s EF-14 trial in
newly diagnosed GBM, Dr. Ram
- 1:50 to 2:05 p.m.: TTFields and brain
metastases, Dr. Gondi
- 2:05 to 2:15 p.m.: TTFields and
non-small cell lung cancer, Dr. Kirson
- 2:30 to 2:55 p.m.: TTFields and
pancreatic cancer, results from Novocure’s second cohort of the
PANOVA phase 2 pilot trial in advanced pancreatic cancer, Dr. Von
Hoff
- 2:55 to 3:10 p.m.: TTFields and ovarian
cancer, results from Novocure’s INNOVATE phase 2 pilot trial in
recurrent ovarian cancer, Dr. Kirson
- 3:10 to 3:25 p.m.: TTFields and
mesothelioma, interim results from Novocure’s STELLAR phase 2 pilot
trial in mesothelioma, Dr. Weinberg
- 3:25 to 3:40 p.m.: What’s next for
TTFields, Dr. Kirson
- 3:40 to 3:55 p.m.: Novocure
engineering, Mr. Ambrogi
- 3:55 p.m.: Closing comments, Mr.
Doyle
A live webcast will be accessible during the event on
Novocure.com and will not be archived on Novocure’s website
following the event. The PowerPoint presentation will be available
on Novocure.com for at least 14 days following the event. To attend
the event, email investorinfo@novocure.com.
About Novocure
Novocure is a commercial-stage oncology company developing a
novel, proprietary therapy called Tumor Treating Fields, or
TTFields, for the treatment of solid tumor cancers. Novocure’s
commercialized product, Optune, is approved for the treatment of
adult patients with glioblastoma. Novocure has ongoing or completed
phase 2 pilot trials investigating TTFields in non-small cell lung
cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York
City. Additionally, the company has offices in Germany, Switzerland
and Japan, and a research center in Haifa, Israel. For additional
information about the company, please visit www.novocure.com or
follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe" or other words and terms of similar meaning.
Novocure's performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on March 1, 2016, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161208005581/en/
Media and Investor ContactNovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Sep 2023 to Sep 2024